

FLEURY S.A.
Public Held Company
Company Taxpayer's ID (CNPJ) 60.840.055/0001-31
Company Registry (NIRE) 35.300.197.534

Material Fact

Fleury SA ("Grupo Fleury" or "Company"), in compliance with paragraph 4 of article 157 of Law 6,404/76 and with CVM's Instruction 358/02, informs to its shareholders and the market in general that, on this date, through its owned subsidiary, Fleury Centro de Procedimentos Médicos Avançados S.A ("Fleury CPMA"), entered into the Quotas Purchase and Sale Agreement and Other Covenants for the acquisition of 100% of the shares issued by Laboratório Pretti Ltda. ("Laboratório Pretti" or "Pretti").

On the same date, Fleury CPMA entered into the Quotas Purchase and Sale Agreement and Other Covenants for the acquisition of 100% of the shares issued by Laboratório Bioclínico Ltda. ("Laboratório Bioclínico" or "Bioclínico").

The conclusion of both transactions is subject to the satisfaction or waiver of certain precedent conditions, as provided for in each of the respective contracts.

The two acquisitions mark the entry of Grupo Fleury in the State of Espírito Santo, and represent another strategic move for the Company, expanding its national reach and further complementing its offer in the Southeast region of the country.

These movements reinforce, above all, the strategy of accelerating growth, with the expansion of services and presence of Grupo Fleury in the healthcare chain, as well as with the continuous strengthening in the diagnostic medicine market.

With these two acquisitions, the Company surpassed the level of R\$ 1 billion invested in acquisitions in the last 5 years - in which it acquired 12 companies that, together, totaled more than 125 Patient Service Centers and more than R\$ 500 million in annual revenues, in addition to investing in Prontmed, Bem.Care, and Sweetch.

About Laboratório Pretti

Laboratório Pretti works with clinical analysis through 25 Patient Service Centers in the metropolitan region of Greater Vitória, being a reference in its area of expertise. It has more than 55 years of experience, an unblemished reputation and respect from the

medical community and its customers.

Pretti's audited gross revenue for the period ended December 31, 2020 reached R\$ 53.6 million.

The Enterprise Value of 100% of Pretti for the purpose of the transaction is R\$ 193.1 million.

About Laboratório Bioclínico

Laboratório Bioclínico is a traditional clinical analysis laboratory that operates in the metropolitan region of Greater Vitória through 15 Patient Service Centers. It has a consolidated track record of 33 years and a high reputation with the medical community and its customers.

The audited gross revenue of Bioclínico, for the period ended on December 31, 2020, reached R\$ 42.0 million.

The Enterprise Value of 100% of Bioclínico for the purpose of the transaction is R\$ 122.0 million.

None of the operations is subject to the Company's shareholders' decision, nor will it give rise to the right to withdraw, in view of the terms of item 7.11 of Official Letter CVM/SEP/No. 01/2021.

The Company will keep its shareholders and the market informed about the facts related to both transactions.

São Paulo, June 1st, 2021

FERNANDO AUGUSTO RODRIGUES LEÃO FILHO

Chief Financial and Investor Relations Officer